Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients (TGC-fast)

  • End date
    Jan 28, 2026
  • participants needed
  • sponsor
    KU Leuven
Updated on 14 February 2022
critical illness
enteral nutrition


Critically ill patients usually develop hyperglycemia, which is associated with an increased risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose concentrations with insulin therapy, referred to as tight blood glucose control (TGC) improves outcome of these patients, as compared to tolerating hyperglycemia. It remains unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC is beneficial in adult critically ill patients not receiving early parenteral nutrition, as compared to tolerating hyperglycemia.

Condition Critical Illness, Hyperglycemia
Treatment insulin
Clinical Study IdentifierNCT03665207
SponsorKU Leuven
Last Modified on14 February 2022


Yes No Not Sure

Inclusion Criteria

Adult patient (18 years or older) admitted to a participating intensive care unit (ICU)

Exclusion Criteria

Patients with a do not resuscitate (DNR) order at the time of ICU admission
Patients expected to die within 12 hours after ICU admission (= moribund patients)
Patients able to receive oral feeding (not critically ill)
Patients without arterial and without central venous line and without imminent need to place it as part of ICU management (not critically ill)
Patients previously included in the trial (when readmission is within 48 hours post ICU discharge, the trial intervention will be resumed)
Patients included in an IMP-RCT of which the PI indicates that co-inclusion is prohibited
Patients transferred from a non-participating ICU with a pre-admission ICU stay >7 days
Patients planned to receive parenteral nutrition during the first week in ICU
Patients suffering from diabetic ketoacidotic or hyperosmolar coma on ICU admission
Patients with inborn metabolic diseases
Patients with insulinoma
Patients known to be pregnant or lactating
Informed consent refusal
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note